, an agonist for four of the five known sphingosine-1-phosphate (S1P) receptors, has been reported to inhibit acute graft-versus-host disease (aGVHD). Because FTY720 functions through multiple S1P receptors, the mechanism of action through one or more of these receptors may account for its side effects. Thus, more selective S1P receptor modulators are needed to evaluate the roles of different S1P receptors and their therapeutic efficacies. In this study, we investigated the effect of an S1P 1 -selective agonist, CYM-5442, on the progression of aGVHD. We showed that CYM-5442 significantly inhibited but did not prevent aGVHD. CYM-5442 did not affect the infiltration of the donor T cells into the target organs, while the number of macrophages in GVHD organs was significantly reduced by CYM-5442 treatment. In vivo proliferation assays showed that the proliferation of macrophages was not suppressed by CYM-5442. Further studies using human endothelial cells demonstrated that CYM-5442 treatment downregulated CCL2 and CCL7 expression in endothelial cells, therefore reducing the migration of monocytes, from which tissue macrophages originate. Our data demonstrate the therapeutic efficacy of an S1P 1 -selective agonist in aGVHD and its possible mechanism of action. The results suggest that further investigations are needed regarding CYM-5442 as a potential therapeutic regimen for aGVHD.
INTRODUCTION
Acute graft-versus-host disease (aGVHD) is one of the major complications of allogeneic hematopoietic stem cell transplantation. It is induced by donor T cells and inflammatory cytokines causing damage to host epithelial tissues, predominantly the skin, liver and gastrointestinal tract. [1] [2] [3] Despite pharmacological prophylaxis, about half of the patients receiving allogeneic hematopoietic stem cell transplantation experience severe aGVHD, which requires high-dose steroid treatment and often has a highly unsatisfactory outcome. Therefore, an immunomodulatory regimen is urgently needed for aGVHD prevention and treatment.
The bioactive lipid sphingosine-1-phosphate (S1P) is involved in various cellular responses such as cell proliferation, platelet aggregation, endothelial cell chemotaxis, and lymphocyte trafficking. [4] [5] [6] [7] S1P is mainly produced by erythrocytes and endothelial cells. S1P binds to five known G protein-coupled receptors, S1P [1] [2] [3] [4] [5] , and acts as a second messenger during cell signaling. 8, 9 Most S1P-dependent immune modulations were discovered using the receptor agonist FTY720. 10, 11 The binding of FTY720 to S1P 1, 3, 4, 5 induces receptor internalization and results in functional antagonism. 9, 12, 13 FTY720 has been shown to be a promising immunosuppressive agent for the treatment of autoimmune disease, promotion of solid organ engraftment and inhibition of aGVHD. 8, [14] [15] [16] [17] [18] [19] [20] [21] However, the mechanism underlying the action of FTY720 is not completely known. Clinically, FTY720 mediates both lymphopenia and transient dose-dependent bradycardia on initial dosing in humans. 22 Because FTY720 acts through multiple S1P receptors, the mechanism of action through one or more of these receptors may account for its side effects. Thus, more selective S1P receptor modulators are needed to evaluate the roles of the different S1P receptors and their therapeutic efficacy.
It has been suggested that the immunosuppression and lymphocyte sequestration caused by FTY720 is primarily mediated by S1P 1 . 4, 5, 9, [23] [24] [25] CYM-5442 (CYM) is an S1P 1 -selective agonist, specifically a sphingosine-like fungal metabolite. 24 CYM is a full agonist in vitro for S1P 1 internalization and phosphorylation. In vivo, it induces S1P 1 -dependent lymphopenia in a manner dependent on both dose and time. CYM is modestly orally bioavailable, with a half-life of 3 h. Although S1P 1 is expressed on both endothelial cells and lymphocytes, S1P 1 signaling in endothelial cells has been shown to be essential for cytokine storms that induce mortality during influenza infection.
Macrophages are recruited from the blood to sites of inflammation by chemokine gradients. CCL2 (MCP-1) and CCL7 (MCP-3) are the primary chemokines that regulate monocyte recruitment in response to inflammation. S1P might also be involved in macrophage trafficking.
3,26-29 FTY720 reduces macrophage infiltration into sites of inflammation in many inflammatory disease models. [30] [31] [32] [33] The mechanism of action of FTY720 may involve its effects on endothelial cells to reduce monocyte migration. 34 This study shows that the S1P 1 -selective agonist CYM inhibited aGVHD by reducing macrophage infiltration at GVHD sites. CYM may act directly on endothelial cells to affect CCL2 and CCL7 production. These results provide evidence for the therapeutic potential of using S1P 1 -selective agonists in treating aGVHD and elucidate the importance of endothelial cells in mediating monocyte migration during CYM treatment.
MATERIALS AND METHODS
) and C57BL/6 (H2 b ) mice were purchased from SLAC Laboratory Animal Center (Shanghai, China). Mice were housed in a specific pathogen-free facility and were used at the age of 8-12 weeks. All animal protocols were approved by the Ethical Committee of Soochow University. All invasive procedures were performed under isofurane anesthesia, and efforts were made to minimize suffering at all times. Animals were sacrificed in their home cage by CO 2 inhalation, followed by exsanguination by cardiac puncture to obtain blood. All other tissues were harvested in a sterile hood following cardiac puncture.
Reagents and cell lines CYM (2-(4-(5-(3,4-diethoxyphenyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl amino) ethanol) and RS102895 were purchased from Sigma-Aldrich (St Louis, MO, USA). FTY720 (2-amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol, hydrochloride) was purchased from Cayman Chemical Company (Ann Arbor, MI, USA). Human umbilical vein endothelial cells (HUVECs) were provided by Dr Quansheng Zhou (Cyrus Tang Hematology Center, Soochow University). HUVECs were cultured with Delbecoo's modified eagle media (DMEM) containing 10% fetal bovine serum (FBS). ) bone marrow cells and 5310 6 whole splenocytes 4 h later. CYM (3 mg/kg), 5, 27, 28 control water, or FTY720 was intraperitoneally injected daily from day 21 to day 3 post allogeneic bone marrow transplantation (BMT). Ten mice per group were monitored daily for survival, were weighed every 3 days, and were thereafter examined for the clinical characteristics of aGVHD. The degree of systemic GVHD was assessed by a scoring system that sums changes in five clinical parameters: weight loss, posture (hunching), activity, fur texture and skin integrity. 35 Histology Livers, lungs and small intestines were harvested from mice 4 days post allo-BMT and were fixed in 10% paraformaldehyde. Livers were perfused before harvesting. Paraffin-embedded fixed tissues were sectioned at 5 mm thickness and were stained with hematoxylin and eosin. Pictures of hematoxylin and eosin sections were acquired in an Olympus upright fluorescence microscope (Tokyo, Japan). Magnification was 3200 or 3400.
Establishment of an aGVHD model

Flow cytometry
Mice were killed 4 days after allo-BMT, and spleens, livers, lungs and small intestines of each mouse treated with CYM or the control reagent (six mice per group) were harvested. Livers were perfused before harvesting. Single-cell suspensions were prepared, and red blood cells were lysed. All samples were incubated with Mouse Fc block (anti-mouse CD16/32; BD Biosciences, San Diego, CA, USA) for 10 min and were then stained with the following mouse-specific monoclonal antibodies (BD Biosciences): FTTC-conjugated CD69, PEconjugated H2K b , PE-TexasRed-conjugated CD3, PerCPCy5.5-conjugated NK1.1, APC-conjugated CD8, APC-H7-conjugated CD4, FTTC-conjugated H2K b , PE-conjugated CD11b, PETexasRed-conjugated CD3, PerCPCy5.5-conjugated Gr-1, PE-Cy7-conjugated CD11c, PerCPCy5.5-conjugated F4/80. Intracellular Staining: Single cell suspensions of spleens, livers, lungs and small intestines were prepared and incubated with 1-Methoxy-2-propylacetate (PMA) (50 ng/ml), Iomomycin (500 ng/ml) and brefeldin (BFA) (10 mg/ml) at 37uC and 5% CO 2 for 4 h. Suspensions were then stained with PE-conjugated anti-CD4 antibody (BD Biosciences) for 30 min at 4 uC. After the wash with phosphate buffered saline (PBS), the cells were fixed with 4% paraformaldehyde and permeabilized with 1% saponin (Sigma-Aldrich) and were then stained with the following mouse-specific monoclonal antibodies: FTTC-conjugated IL-17A, APC-conjugated IL-4, APC-conjugated IFN-c or control isotype antibody. Samples were acquired in a FACS Canto II (BD Biosciences) equipped with a 488 nm argon laser and a 635 nm red diode laser. Data were analyzed with FlowJo Software (FlowJo, Ashland, OR, USA).
In vivo cell proliferation assay Mice were intraperitoneally injected with EdU 24 h before the analysis. Single-cell suspensions of lymphocytes isolated from spleens, livers, lungs and small intestines were incubated with 
Adoptive transfer of macrophages
Macrophages from bone marrow of donor C57BL/6 mice were sorted and labeled with carboxy fluorescein succinimidyl amino ester (CFSE) (Invitrogen) according to the manufacturer's instructions. Macrophages labeled with CFSE were adoptively transferred into mice treated with CYM or control mice. After 30 h, single-cell suspensions of lymphocytes were isolated from livers, lungs and small intestines, and the samples were acquired in a FACS Canto II (BD Biosciences). Data were analyzed with FlowJo Software (FlowJo).
Real-time PCR
HUVECs were plated at 5310 6 per well in six-well plates and were then cultured overnight. The cells were treated with CYM (0.1 mM or 1 mM final concentration) or an equal volume of dimethyl sulfoxide (DMSO) for 24 h. Then, the cells were washed twice with PBS, and total RNA was extracted using TRizol (Invitrogen) according to the manufacturer's instructions. The total RNA was reverse transcribed to prepare cDNA. The mRNA levels of CCL2, CCL7, CXCL1 and CXCL5 were detected by real-time PCR using Power SYBR Green Master Mix (Applied Biosystems, Warrington, UK). bactin was simultaneously amplified as an internal reference. The primer sequences are as follows: CCL2 forward: agtgtcccaaagaagctgtg; CCL2 reverse: gattcttgggttgtggagtg; CCL7 forward: ttttggtgggttttgaacat, CCL7 reverse: tgcttccatagggacatcat; CXCL1 forward: ttgaaatgtcaaccccaagt, CXCL1 reverse: cctgccttcacaatgatctc; CXCL5 forward: atccagaagccccttttcta and CXCL5 reverse: gaggaatccaggaagaaagc.
Transwell assay
Peripheral blood mononuclear cells (PBMCs) was isolated from the peripheral blood by Ficoll, washed twice with 13 PBS and stained with anti-CD14 monoclonal antibody at 4 uC for 30 min. After washing, CD14 1 cells were sorted by FACS Aria (BD Bioscience) . Sorted monocytes were incubated with 10 ng/ml or 100 ng/ml RS102895, or with DMEM at 37 uC and 5% CO 2 for 30 min; then, the monocytes were washed with DMEM three times. The monocytes (5310 5 /200 ml) were added to the upper wells. Five hundred microliters of supernatant of HUVECs treated for 24 h with CYM (1 mM final concentration) or with an equal volume of DMSO was plated in the lower wells. The plate was incubated at 37 uC for 6-8 h, and the cells that migrated to the lower wells were then counted and analyzed.
Serum cytokine measurement
Serum was collected from mice on day 4 after allo-BMT. Serum cytokine levels, including IL-2, IL-4, IL-6, IL-10, IL-17A, IFN-c and TNF, were measured using Mouse Th1/Th2/Th17 CBA Kits (BD Bioscience), according to the manufacturer's instructions. Samples were acquired with a FACS Canto II (BD Biosciences), and the data were analyzed with FlowJo Software (FlowJo). Serum levels of CCL2 and CCL7 were measured using the mouse MCP-1/CCL2 ELISA kit (Biolegend, San Diego, CA, USA) and the mouse MCP-3/CCL7 ELISA kit (R&D, Piscataway, NJ, USA) according to the manufacturer's instructions.
Statistical analysis
Survival data were analyzed by a log-rank test. Group comparisons were made with a two-tailed Student's t-test. Data were analyzed using GraphPad Prism 5 software for Windows (GraphPad Software, San Diego, CA, USA), and the differences were considered statistically significant when P,0.05.
RESULTS
CYM-5442 inhibits but does not prevent aGVHD
To assess the effect of the S1P 1 selective agonist CYM on aGVHD progression, we used a major MHC-mismatched allogeneic BMT model (B6RBALB/c) and transplanted lethally irradiated BALB/c mice with 1310 7 C57BL/6 TCD-BM cells and whole spleen cells (5310 6 ). CYM (3 mg/kg) or control reagent was intraperitoneally injected once daily from day 21 to day 3 post bone marrow transplantation. CYM treatment dramatically prolonged the survival of GVHD mice compared with control-treated mice (Figure 1a ; P,0.0001). An improved therapeutic effect was observed with CYM treatment compared with FTY720 treatment at the dose of 3 mg/kg in our model (Supplementary Figure 1) . Body weight loss of GVHD mice and GVHD scores were also reduced by administration of CYM (Figure 1b and c) . However, all the CYM-treated mice eventually died from aGVHD. On day 4 post allogeneic BMT, the target organs in control mice showed typical characteristics of aGVHD, such as incomplete intestinal villus epithelial structure and epithelial cell shedding (Figure 1d ). In contrast, the target organs of CYM-treated mice showed reduced GVHD characteristics. Therefore, CYM treatment could significantly prolong the survival of aGVHD mice, but could not completely prevent the incidence of aGVHD.
CYM does not affect the infiltration of donor T cells to the GVHD target organs, but reduces their activation
To determine whether CYM treatment could affect donor lymphocyte infiltration to the GVHD target organs, we examined the number of donor-and host-derived CD4 CYM significantly reduces the number of macrophages in the aGVHD target organs without directly affecting their proliferation Myeloid cells are reported to play an important role in the early immune response of GVHD mice. 29 We also monitored the changes of myeloid cells in the GVHD target organs with and without CYM treatment. As with the DCs shown in Figure 2 , neutrophil numbers in the GVHD target organs were not affected by CYM treatment (data not shown). Interestingly, both the percent and number of macrophages were significantly reduced by CYM treatment in the liver and lung, but increased in the spleen on day 4 post BMT (Figure 4a-c) . The percent and number of macrophages in the intestine were not affected by CYM treatment. These results suggest that the migration of macrophages from the lymphoid organ to the GVHD target 10  40  1  24  20  18  16  14  12  11  10  9  8  7  3  2 8   24  20  18  17 19  16  15  14  13  12  11  10  9  8  7 organs, including the liver and lung, was inhibited by CYM. To further determine whether the decreased number of macrophages was caused by a direct effect of CYM on macrophage proliferation, the in vivo EdU assay was performed. CYM showed no effect on both the percentage and number of EdU 1 macrophages, suggesting the proliferation of macrophages was not inhibited by CYM treatment (Figure 4d and e). To further determine whether the migration of macrophages to the GVHD target organs were inhibited by CYM treatment, CFSE-labeled bone marrow macrophages were adoptively transferred into CYM-treated and control mice (Figure 4f and g) . After 30 h, the transferred macrophages were analyzed in the spleen, liver, lung and intestine. The percent and number of transferred macrophages in the spleen were similar for CYM-treated and control mice. However, the percent of transferred macrophages was significantly lower in all of the GVHD target organs examined for CYM-treated mice compared with the control mice. The numbers of transferred macrophages were also significantly lower in the liver and lung of CYM-treated mice compared with the control mice. Therefore, the results indicate that treatment with the S1P 1 -selective agonist CYM reduced macrophage migration to GVHD target organs.
CYM inhibits monocyte migration by reducing the production of CCL2 and CCL7 by endothelial cells It has been shown that endothelial cells are the key regulators of cytokine storm and innate cell migration to inflammatory sites. 5 A potential mechanism by which CYM inhibits macrophage migration to the GVHD target organs is by reducing chemokine production by endothelial cells. To test this hypothesis, we examined the chemokine production of the human endothelial cell line HUVEC, which expressed S1P 1 after CYM treatment. Both 0.1 mM and 1 mM of CYM significantly downregulated the mRNA expression of CCL2 and CCL7 in HUVECs (Figure 5a and b) . However, two other chemokines that could affect monocyte migration, CXCL1 and CXCL5, were not affected by CYM treatment ( Supplementary Figure 3a and b) . Another human endothelial cell line that also expresses S1P 1 , HLMVEC, showed similar results (data not shown).
To determine whether CCL2 and CCL7 could be the key chemokines affected by CYM to reduce monocyte migration through interaction with their receptor CCR2, we sorted monocytes from the peripheral blood and incubated them with or without the CCR2 antagonist RS102895 for 30 min at 37 uC before the transwell assay. Without RS102895 treatment, the number of monocytes that migrated into the lower wells was significantly decreased when the CYM-treated HUVEC supernatant was placed in the lower wells compared with the control-treated HUVEC supernatant (Figure 5c ). This result demonstrates that CYM significantly suppressed the chemoattractant ability of endothelial cells for monocyte migration. With RS102895 treatment, monocyte migration to the lower wells with control-treated HUVEC supernatant was significantly reduced in a dose-dependent manner, eventually to a level similar to that when CYM-treated HUVEC supernatant was used. RS102895 treatment did not affect monocyte migration with the CYM-treated HUVEC supernatant, suggesting that the interaction between CCR2 and its ligands was already blocked with CYM treatment. To confirm this finding in vivo, we measured the serum levels of CCL2 and CCL7 in CYMtreated and control mice (Figure 5d and e) . Both CCL2 and CCL7 levels were decreased by CYM treatment. These results indicate that the S1P 1 -selective agonist CYM inhibited CCL2 and CCL7 production by the endothelial cells and therefore reduced both the migration of monocytes through the blood vessels and the infiltration of macrophages to the GVHD target organs.
DISCUSSION
The recruitment of innate immune cells to the GVHD organs and the excessive production of proinflammatory cytokines and chemokines are hallmarks of the initial stage of aGVHD. 36 This study demonstrates that the S1P 1 -selective agonist CYM could inhibit aGVHD by preventing macrophage recruitment to the GVHD target organs. Our results also indicate that CYM could modulate chemokine production by endothelial cells, thereby affecting monocyte migration. This is the first report on the role of an S1P 1 -selective agonist in aGVHD, and our data indicate that the S1P 1 receptor on endothelial cells might be critical for monocyte recruitment during the initial stage of aGVHD.
The S1P 1 -selective agonist CYM has been shown to induce reversible lymphopenia and ameliorate the murine model of multiple sclerosis. 37 However, in the model of atherosclerosis in Low-density lipoprotein (LDL) receptor-deficient mice, FTY720 lowered blood lymphocytes while CYM did not, suggesting that these two S1P receptor agonists may have different mechanisms. 38 In our model of aGVHD, CYM did not induce obvious lymphopenia. We did not observe any effect of CYM on the infiltration of donor T cells to the aGVHD organs at an early stage of the disease. Although it has been suggested that FTY720 may modulate lymphocyte trafficking, especially donor-derived T-cell infiltration into target organs, to inhibit aGVHD, 20, 39, 40 another recent study demonstrated that FTY720 did not inhibit donor effector T-cell trafficking into the aGVHD target organs. 41 The same report also showed FTY720 reduced the number of DCs in the target organs, which has been suggested to be the mechanism underlying aGVHD inhibition. We did not observe any changes in DCs in the GVHD target organs with CYM treatment. However, CYM treatment was associated with significantly fewer macrophages in GVHD target organs. The difference in the number of DCs induced by FTY720 treatment may not be due to a blockade of the S1P 1 receptor, and the numbers of macrophages were not noted specifically in that study. Both FTY720 and CYM were found to reduce the activity of splenic and peritoneal macrophages in the murine atherosclerosis model, 38 suggesting that S1P 1 signaling could be critical to macrophage activity. In this study, there were more macrophages in the spleen, but their migration to the GVHD target organs was inhibited by CYM treatment. Because the hematopoietic reconstitution is far from complete at the early time points after hematopoietic stem cell transplantation, the numbers of macrophages are very low at the GVHD target organs. Although the percent and number of macrophages showed only slight reductions in the liver and lung after CYM treatment, the differences were statistically significant. Bone marrow macrophages from CYMtreated mice showed even higher levels of tumor necrosis factor (TNF) and IL-6 production upon Lipopolysaccharides (LPS) stimulation than those from the control mice (our unpublished data). This result suggests that the function of macrophages was not suppressed systemically by CYM treatment. The increased cytokine release from the bone marrow macrophages after stimulation may even suggest reduced migration of the activated macrophages into the GVHD organs. Because the number of infiltrating macrophages was very low, it was difficult to sort out enough cells to perform functional assays. Future studies are needed to determine the function of the infiltrating macrophages in the GVHD target organs. Macrophage infiltration into target organs has been shown to be an important event during aGVHD. 42, 43 One retrospective clinical study investigated the relationship between the types of infiltrating cells and the clinical outcomes of GVHD. 44 The number of macrophages that infiltrated skin lesions was shown to be a significant predictive factor for refractory GVHD and a poor prognosis, but the number of T cells was not. Macrophages may function as antigen-presenting cells during the initial stage of aGVHD, but also to provide pro-inflammatory cytokines to initiate the alloreactive adaptive immune response. Human monocytes express S1P receptors 1, 2 and 4, and human macrophages express S1P receptors 1, 2, 3 and 4. 45 An S1P 1 -selective agonist may act directly on macrophage proliferation and trafficking. [26] [27] [28] [29] 46 An in vivo proliferation assay demonstrated that CYM did not affect macrophage proliferation. Increasing amounts of data have indicated that the lower number of macrophages in the inflamed tissues of FTY720-treated mice could be an indirect effect of vascular permeability and monocyte recruitment.
CYM inhibited but did not prevent aGVHD when given on day 21 to day 3 post transplantation. Because of the short half-life of CYM, continuous administration could result in better efficacy. Because early events of cell trafficking are critical for aGVHD pathogenesis, we performed all of the analysis on day 4, one day after the last CYM treatment. FTY720 has also been shown to only inhibit aGVHD, 41 similar to our results. Additionally, the same study proposes that the primary function of FTY720 may be targeted to host cells, as indicated by the fact that FTY720 treatment prior to transplantation inhibited GVHD, but continuous administration for up to 28 days after transplantation did not significantly prolong survival. This could also be the case for CYM. However, further investigation must be performed before a more effective therapeutic schedule can be developed.
Some S1P receptor agonists, including the S1P 1 -selective agonist KRP203, are currently in clinical trials for the treatment of autoimmune disease. 47 SEW2871, a selective S1P 1 agonist, has been shown to be effective in protecting kidneys against ischemia-reperfusion injury by reducing CD4
1 T-cell infiltration in mice. 48 AUY954, which selectively targets S1P 1 , is known to sequester lymphocytes into secondary lymphoid tissues. In experimental autoimmune neuritis rats, AUY954 greatly prevented paraparesis if administered from the day of immunization. 49 Therefore, a study of the role of other selective S1P 1 agonists in acute GVHD is warranted in the future. Moreover, silencing S1P 1 expression using other methods including siRNA/shRNA may further confirm the critical role of S1P 1 during the pathogenesis of acute GVHD. Binding of S1P receptor agonists, including FTY720 and CYM, to S1P receptors causes internalization and may cause functional antagonism, persistent signaling or both. 12, 50, 51 The ways in which internalization, degradation, and sustained signaling collectively regulate S1P receptor function are not yet understood. Further studies are needed to fully elucidate the molecular mechanism by which the S1P agonists act.
In summary, the current work demonstrates that the S1P 1 -selective agonist CYM can inhibit aGVHD and provides insight into the mechanism of action. CYM may provide a more specific clinical strategy than FTY720 for controlling aGVHD.
